Topical Mustine Hydrochloride and Psoriasis

Purdy, M. J.

doi:10.1111/j.1440-0960.1973.tb00701.x

Cited by 3 publications

(2 citation statements)

References 7 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…of patients with CD (%) No. of patients with treatment discontinuation due to CD (%) Van Scott et al [ 4 ] 3 0.002% to 0.025% Single dose to 1 lesion under occlusion 3/3 (100%) lesions Not reported Not reported Not reported Not reported Epstein et al [ 5 ] 12 0.05% Weekly to lesions 10/12 (83%) patients 3/10 (30%) patients 2 to > 10 months after discontinuation 9/12 (75%) 6/12 (50%) Mandy et al [ 6 ] 7 0.02% Once daily to lesions 7/7 (100%) patients 7/7 (100%) patients 1–5 months on maintenance 1/7 (14%) 0/7 (0%) Zackheim et al [ 7 ] 42 0.0125%, 0.025% and 0.05% Once daily to up to 4 lesions 37/42 (88%) lesions 32/42 (76%) lesions 0–6 months after discontinuation 23/42 (55%) Not reported Purdy [ 8 ] 29 0.02% Once daily to lesions 27/29 (93%) patients 27/29 (93%) patients 2–16 months on maintenance 10/35 (29%) 4/35 (43%) Price [ 9 ] 10 0.00001% to 0.01% Once daily to lesions 9/10 (90%)...…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Topical Mechlorethamine for the Treatment of Psoriasis: A Report of Two Cases and Literature Review

Fahmy

Kwinta

Schreidah

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Psoriasis is a common inflammatory skin disease that significantly impacts patients' psychosocial wellbeing. Despite increasingly effective treatment options, the recurrence of plaques after discontinuation of therapy in many patients highlights the need for additional therapies. Methods: We report two cases of patients with concurrent psoriasis and mycosis fungoides who were treated with topical mechlorethamine (MCH). A literature review was performed by searching PubMed using the keywords psoriasis, mechlorethamine, chlormethine, and nitrogen mustard. Results: Both patients had significant improvement in their psoriasis following treatment with topical MCH gel, which was well tolerated and maintained clearance after 1 and 3 years of follow-up. Seven prospective cohort studies investigating the use of topical MCH were identified through literature review. Out of five studies reporting clinical outcomes by patient, 68 of 77 patients (88%) experienced an improvement in their psoriasis, with 47 of 77 (61%) achieving complete or near-complete clearance. The remaining two studies reported clinical outcomes by lesion, demonstrating improvement in 40 of 45 lesions (88%) and complete or near-complete clearance in 32 of 42 lesions (76%). Contact dermatitis was the most frequent adverse effect, observed in 56 of 125 patients (45%). Conclusions: Topical MCH may be an option for patients with psoriasis who fail or have incomplete responses to other treatments. Published studies are limited by lack of standardized treatment regimens and well-defined outcome measures, highlighting the need for prospective clinical trials to better understand the utility of this topical agent in psoriasis.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Seven prospective cohort studies investigating the use of topical MCH in psoriasis were included [4][5][6][7][8][9][10] (Table 1). Clinical outcomes were either reported by patient or by lesion.…”

Section: Literature Review: Efficacy Of Topical Mch In Psoriasismentioning

confidence: 99%

Topical Mechlorethamine for the Treatment of Psoriasis: A Report of Two Cases and Literature Review

Fahmy

Kwinta

Schreidah

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

The uses of systemic chemotherapeutic agents in psoriasis

McDonald

1981

Pharmacology & Therapeutics

View full text Add to dashboard Cite